Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EBIO

Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis

Eleven Biotherapeutics logo

About Eleven Biotherapeutics Stock (NASDAQ:EBIO)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
15.58 million shs
Average Volume
2.86 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive EBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EBIO Stock News Headlines

Atara Biotherapeutics Inc.
Flagship Ventures Fund IV-Rx, L.P.'s Net Worth
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
See More Headlines

EBIO Stock Analysis - Frequently Asked Questions

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Sesen Bio (SESN), TransEnterix (TRXDW) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/15/2018
Today
10/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EBIO
CIK
1485003
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:EBIO) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners